Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase NA 7Phase 3 2Phase 1/2 2Phase 1 2

Status

Terminated 4Unknown 3Completed 3Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 157Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 90Pancreatic Neoplasms 81Leukemia, Myeloid, Acute 81Recurrence 78Neoplasm Metastasis 78Prostatic Neoplasms 73Melanoma 73Ovarian Neoplasms 72Multiple Myeloma 66Stomach Neoplasms 60Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 43Advanced Solid Tumor 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 37Uterine Cervical Neoplasms 35Small Cell Lung Carcinoma 35Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × NSCLC × Clear all
NCT06940401 2025-05-14

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Suzhou Junjing BioSciences Co., Ltd.

Phase 1/2 Recruiting
42 enrolled
Thoracic

NSCLC

NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
110 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡